A B S T R A C T
Background and Objectives
Graft-versus-host disease (GVHD) remains one of the most important challenges and life-threatening complications following allogeneic hematopoietic stem cell transplantation (HSCT). Given the limitations and potentially severe adverse effects of conventional immunosuppressive therapies and corticosteroids, the application of mesenchymal stem cells (MSCs) has attracted considerable attention as a novel cell-based therapeutic strategy. This review aims to elucidate the mechanisms of action, evaluate the available clinical evidence, and define the paradigm of MSCs in various GVHD management strategies, encompassing prophylaxy and primary treatments, as well as salvage therapy for steroid-refractory cases.
Materials and Methods
This study was designed as a narrative review. A literature search was conducted in major scientific databases, including PubMed, Scopus, and Web of Science. The main search terms included “Mesenchymal Stem Cells,” “Graft-Versus-Host Disease,” “Immunomodulation,” and “Cell Therapy.” Articles published between 2000 and 2026 were retrieved. Basic studies and clinical trials investigating the role of MSCs in the prevention and treatment of acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD) were included. Review articles, editorials, letters to the editor, conference abstracts, duplicate publications, and studies not directly related to MSC-based interventions in GVHD were excluded. Retrieved records were first screened by title and abstract, followed by full-text assessment for relevance. Studies were selected based on their relevance to the therapeutic mechanisms, clinical efficacy, the limitations and transfer capacity of MSCs in the context of GVHD were investigated.
Results
Accumulating clinical and preclinical evidence indicates that mesenchymal stem/stromal cells (MSCs) exert their therapeutic effects through diverse mechanisms, including the secretion of paracrine factors and direct cell–cell interactions. These mechanisms contribute to the attenuation of cytokine storm and promote the induction of regulatory T cells (Tregs). The clinical applications of MSCs can be broadly categorized into two main areas: prophylactic administration (concomitant with transplantation) and therapeutic use, particularly as salvage therapy in steroid-refractory cases.
Conclusions
By shifting the inflammatory response towards immune tolerance, MSCs represent a highly powerful tool in controlling GVHD. Nevertheless, the standardization of optimal dosing and cellular sources, along with further investigation of cell-free derivatives, such as exosomes, is essential for optimizing this treatment strategy in the future.